Please login first
Madalena Pinto   Professor  Senior Scientist or Principal Investigator 
Timeline See timeline
Madalena Pinto published an article in April 2019.
Top co-authors See all
Artur M. S. Silva

801 shared publications

University of AveiroChemistry Campus Universitário de Santiago 3810-193 Aveiro PORTUGAL

Maria João Rocha

295 shared publications

Department of Ophthalmology, Otorhinolaryngology, and Head and Neck Surgery, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil

Maria De Lourdes Bastos

273 shared publications

UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

Madalena M.M. Pinto

257 shared publications

LQOF—Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal

Anake Kijjoa

153 shared publications

CIIMAR - Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros de Leixões, Avenida General Norton de Matos s/n, 4450-208 Matosinhos, Portugal; ICBAS - Abel Salazar Biomedical Sciences Institute, University of Porto, Rua Jorge de Viterbo Ferreira, 228, 4050-313 Porto, Portugal

241
Publications
278
Reads
33
Downloads
229
Citations
Publication Record
Distribution of Articles published per year 
(1974 - 2019)
Total number of journals
published in
 
33
 
Publications See all
Article 0 Reads 2 Citations New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma Sara Gomes, Liliana Raimundo, Joana Soares, Joana B. Loureir... Published: 01 April 2019
Cancer Letters, doi: 10.1016/j.canlet.2019.01.014
DOI See at publisher website
Article 1 Read 0 Citations Antithrombotics from the Sea: Polysaccharides and Beyond Francisca Carvalhal, Ricardo R. Cristelo, Diana I. S. P. Res... Published: 16 March 2019
Marine Drugs, doi: 10.3390/md17030170
DOI See at publisher website ABS Show/hide abstract
Marine organisms exhibit some advantages as a renewable source of potential drugs, far beyond chemotherapics. Particularly, the number of marine natural products with antithrombotic activity has increased in the last few years, and reports show a wide diversity in scaffolds, beyond the polysaccharide framework. While there are several reviews highlighting the anticoagulant and antithrombotic activities of marine-derived sulfated polysaccharides, reports including other molecules are sparse. Therefore, the present paper provides an update of the recent progress in marine-derived sulfated polysaccharides and quotes other scaffolds that are being considered for investigation due to their antithrombotic effect.
Article 4 Reads 0 Citations Chiral Stationary Phases for Liquid Chromatography: Recent Developments Joana Teixeira, Maria Elizabeth Tiritan, Madalena M. M. Pint... Published: 28 February 2019
Molecules, doi: 10.3390/molecules24050865
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
The planning and development of new chiral stationary phases (CSPs) for liquid chromatography (LC) are considered as continuous and evolutionary issues since the introduction of the first CSP in 1938. The main objectives of the development strategies were to attempt the improvement of the chromatographic enantioresolution performance of the CSPs as well as enlarge their versatility and range of applications. Additionally, the transition to ultra-high-performance LC were underscored. The most recent strategies have comprised the introduction of new chiral selectors, the use of new materials as chromatographic supports or the reduction of its particle size, and the application of different synthetic approaches for preparation of CSPs. This review gathered the most recent developments associated to the different types of CSPs providing an overview of the relevant advances that are arising on LC.
Article 0 Reads 0 Citations Synthetic Chiral Derivatives of Xanthones: Biological Activities and Enantioselectivity Studies Carla Fernandes, Maria Letícia Carraro, João Ribeiro, Joana ... Published: 22 February 2019
Molecules, doi: 10.3390/molecules24040791
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
Many naturally occurring xanthones are chiral and present a wide range of biological and pharmacological activities. Some of them have been exhaustively studied and subsequently, obtained by synthesis. In order to obtain libraries of compounds for structure activity relationship (SAR) studies as well as to improve the biological activity, new bioactive analogues and derivatives inspired in natural prototypes were synthetized. Bioactive natural xanthones compromise a large structural multiplicity of compounds, including a diversity of chiral derivatives. Thus, recently an exponential interest in synthetic chiral derivatives of xanthones (CDXs) has been witnessed. The synthetic methodologies can afford structures that otherwise could not be reached within the natural products for biological activity and SAR studies. Another reason that justifies this trend is that both enantiomers can be obtained by using appropriate synthetic pathways, allowing the possibility to perform enantioselectivity studies. In this work, a literature review of synthetic CDXs is presented. The structures, the approaches used for their synthesis and the biological activities are described, emphasizing the enantioselectivity studies.
Article 0 Reads 0 Citations Synthesis of New Proteomimetic Quinazolinone Alkaloids and Evaluation of Their Neuroprotective and Antitumor Effects Solida Long, Diana I. S. P. Resende, Anake Kijjoa, Artur M. ... Published: 01 February 2019
Molecules, doi: 10.3390/molecules24030534
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
New quinazolinone derivatives of the marine-derived alkaloids fiscalin B (3) and fumiquinazoline G (1), with neuroprotective and antitumor effects, were synthesized. Eleven quinazolinone-containing indole alkaloids were synthesized, proceeding the anti analogs via a one-pot method, and the syn analogs by the Mazurkiewicz-Ganesan approach. The neuroprotection capacity of these compounds on the rotenone-damage human neuroblastoma cell SH-SY5y was evaluated using the MTT assay. Compounds 1, 3, 5, and 7 showed more than 25% protection. The antitumor activity was investigated using the sulforhodamine B assay and some compounds were tested on the non-malignant MCF-12A cells. Fumiquinazoline G (1) was the most potent compound, with GI50 values lower than 20 µM. Compounds 5, 7, and 11 were more active in all tumor cell lines when compared to their enantiomers. Compounds 5, 7, 10, and 11 had very little effect in the viability of the non-malignant cells. Differences between enantiomeric pairs were also noted as being essential for these activities the S-configuration at C-4. These results reinforce the previously described activities of the fiscalin B (3) as substance P inhibitor and fumiquinazoline G (1) as antitumor agent showing potential as lead compounds for the development of drugs for treatment of neurodegenerative disorders and cancer, respectively.
Article 0 Reads 0 Citations Discovery of a New Xanthone against Glioma: Synthesis and Development of (Pro)liposome Formulations Ana Alves, Marta Correia-Da-Silva, Claúdia Nunes, João Campo... Published: 23 January 2019
Molecules, doi: 10.3390/molecules24030409
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
Following our previous work on the antitumor activity of acetylated flavonosides, a new acetylated xanthonoside, 3,6-bis(2,3,4,6-tetra-O-acetyl-β-glucopyranosyl)xanthone (2), was synthesized and discovered as a potent inhibitor of tumor cell growth. The synthesis involved the glycosylation of 3,6-di-hydroxyxanthone (1) with acetobromo-α-d-glucose. Glycosylation with silver carbonate decreased the amount of glucose donor needed, comparative to the biphasic glycosylation. Xanthone 2 showed a potent anti-growth activity, with GI50 < 1 μM, in human cell lines of breast, lung, and glioblastoma cancers. Current treatment for invasive brain glioma is still inadequate and new agents against glioblastoma with high brain permeability are urgently needed. To overcome these issues, xanthone 2 was encapsulated in a liposome. To increase the well-known low stability of these drug carriers, a proliposome formulation was developed using the spray drying method. Both formulations were characterized and compared regarding three months stability and in vitro anti-growth activity. While the proliposome formulation showed significantly higher stability, it was at the expense of losing its biocompatibility as a drug carrier in higher concentrations. More importantly, the new xanthone 2 was still able to inhibit the growth of glioblastoma cells after liposome formulation.
Top